典型文献
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer:a retrospective analysis
文献摘要：
Bevacizumab,an anti-VEGF monoclonal antibody,has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC(ns-NSCLC).However,the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation.Thus,59 patients were included in the present retrospective study,22 patients in the bevacizumab plus pemetrexed and platinum(B+PP)group,and 37 patients in the pemetrexed and platinum(PP)group.For the entire cohort of patients,the median OS was 33.3 months,and the 1-year and 2-year overall survival rates were 88.5％and 67.8％,respectively.The median OS and 1-year and 2-year OS rates were 20.5 months,70.3％and 0％,respectively,in the B+PP group and 33.4 months,97.0％and 89.4％,respectively,in the PP group(P＜0.001).The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group(27.3％vs.10.8％,respectively;P=0.204).Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS,whereas the addition of bevacizumab was an unfavorable prognostic factor.With increased toxicities,the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.
文献关键词：
中图分类号：
作者姓名：
Yaru Tian;Hairong Tian;Xiaoyang Zhai;Hui Zhu;Jinming Yu
作者机构：
Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Science,Jinan 250117,China;Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong University,Jinan 250117,China
文献出处：
引用格式：
[1]Yaru Tian;Hairong Tian;Xiaoyang Zhai;Hui Zhu;Jinming Yu-.Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer:a retrospective analysis)[J].医学前沿,2022(04):610-617
A类：
Bevacizumab,B+PP,receipt
B类：
combination,pemetrexed,platinum,elderly,patients,advanced,squamous,small,cell,lung,cancer,retrospective,analysis,VEGF,monoclonal,antibody,has,significantly,improved,clinical,outcomes,NSCLC,ns,However,safety,efficacy,bevacizumab,require,further,investigation,Thus,were,included,present,study,plus,group,For,entire,cohort,median,OS,was,months,year,overall,survival,rates,respectively,incidence,grade,adverse,events,higher,than,Univariate,multivariate,analyses,suggested,that,cycles,first,line,chemotherapy,independent,prognostic,whereas,addition,unfavorable,With,increased,toxicities,does,not
AB值：
0.411099
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
